Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Gitelman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
International Journal of Pediatric Endocrinology|February 12, 2010
Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresisYoon Hi Cho, Stephen Gitelman, Stephen Rosenthal, et al.
Pediatric Diabetes|November 9, 2010
Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population?Nicole S Glaser, David H Geller, Andrea Haqq, et al.
Diabetes|January 30, 2004
Insulin secretion in type 1 diabetesChynna Steele, William A Hagopian, Stephen Gitelman, et al.
Diabetes|February 21, 2013
Immune therapy and β-cell death in type 1 diabetesJasmin Lebastchi, Songyan Deng, Amir H Lebastchi, et al.
Clinical Immunology (Orlando, Fla.)|May 16, 2009
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 yearsKevan C Herold, Stephen Gitelman, Carla Greenbaum, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Xenotransplantation|July 12, 2019
Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptomeLudmilla Le Berre, Richard Danger, Hoa L Mai, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
International Journal of Pediatric Endocrinology|February 12, 2010
Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresisYoon Hi Cho, Stephen Gitelman, Stephen Rosenthal, et al.
Pediatric Diabetes|November 9, 2010
Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population?Nicole S Glaser, David H Geller, Andrea Haqq, et al.
Diabetes|January 30, 2004
Insulin secretion in type 1 diabetesChynna Steele, William A Hagopian, Stephen Gitelman, et al.
Diabetes|February 21, 2013
Immune therapy and β-cell death in type 1 diabetesJasmin Lebastchi, Songyan Deng, Amir H Lebastchi, et al.
Clinical Immunology (Orlando, Fla.)|May 16, 2009
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 yearsKevan C Herold, Stephen Gitelman, Carla Greenbaum, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Xenotransplantation|July 12, 2019
Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptomeLudmilla Le Berre, Richard Danger, Hoa L Mai, et al.
Pageof 1